Previous close | 2.8800 |
Open | 2.8100 |
Bid | 2.8300 x 200 |
Ask | 2.8800 x 600 |
Day's range | 2.8000 - 2.9200 |
52-week range | 0.7900 - 3.7900 |
Volume | |
Avg. volume | 3,079,404 |
Market cap | 188.54M |
Beta (5Y monthly) | 1.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.